Brainstorm Cell Q1 net loss $5.1M; FDA sets ADCOM for NurOwn ALS BLA

BRAINSTORM CELL THERAPEUTICS INC.

2023-Q1 EPS reported -$0.14

Cash and equivalents $2.2M at March 31, 2023, down from $3.0M at Dec 31, 2022.
Net loss of $5.1M ($0.14 per share) vs. $5.4M ($0.15) in Q1 2022.
FDA to hold Advisory Committee meeting to review NurOwn BLA for ALS; PDUFA date to be set.
Appointed Dr. Kirk Taylor as EVP and Chief Medical Officer in April 2023.
R&D expenses $2.9M (up from $2.6M); G&A expenses $2.2M (down from $2.9M) year-over-year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended March 31, 2023 results: net income Net loss ... was approximately $5.1 million, EPS Net loss per share ... was $0.14.

Period: the quarter ended March 31, 2023
Net income: Net loss ... was approximately $5.1 million
EPS: Net loss per share ... was $0.14
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2023 was approximately $5.1 million, as compared to a net loss of approximately $5.4 million for the three months ended March 31, 2022. Net loss per share for the three months ended March 31, 2023 and 2022 was $0.14 and $0.15, respectively.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-060164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.